PTO/SB/08A/B (10-96) Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known Substitute for form 1449A/B/PTO Application Number 09/964,065 PETERMATION DISCLOSURE Filing Date September 26, 2001 First Named Inventor KOVESDI, Imre STATEMENT BY APPLICANT Group Art Unit 1636 /632 FEB 1 9 2002 (Life as many sheets as necessary) Examiner Name Attorney Docket Number Sheet of 3 213257

U.S. PATENT DOCUMENTS U.S. Patent Document Name of Patentee or Applicant of Cited Document Date of Publication of Cited Document MM-DD-YYYY Filing Date If Initials1 Patent Number Class Subclass Appropriate 09-20-1983 Vande Woude 5 4,405,712 435 AA 50° 424 Saito et al. 12-23-1997 570 5,700,470 233.1 AB Kovesdi et al. <del>12-22-1998</del> AC 5,851,106 50P 5,994,106 Kovesdi et al. <del>11-30-199</del>9 AD 50P 508 ΑE 6,127,175 Vigne et al. T<del>0-03-200</del>0

Duplicate

Foreign Patent Document		ıt	I				Translation			
Examiner Initials <sup>1</sup>	Cite No.	Office	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Yes	No*
SDP	AF	AU	94/68503	Α	Transgene S.A.	12-08-1994	1	1		
30P	AG	AU	94/72646	Α	Rhône-Poulenc Rorer	01-26-1995				
55P	АН	CA	2,117,668	Α	Sumitomo Pharm. Co.	09-10-1995				
SOP	ΑI	FR	2707664	Α	CNRS (Paris)	01-20-1995			Х	
SOP	AJ	wo	94/08026	A	Rhône-Poulenc Rorer	04-14-1994				
50P	AK	wo	94/11506	Α	ARCH Devel. Corp.	05-26-1994				
Soc	AL	wo	94/12649	Α	Genzyme Corp.	06-09-1994				
SDP	AM	wo	94/28152	Α	Transgene S.A.	12-08-1994			Χ -	<
50P	AN	wo	94/28938	Α	University of Michigan	12-22-1994				
SOP	A0	wo	95/00655	A	McMaster University	01-05-1995				
SDP	AP	wo	95/26411	Α	UAB Research Found.	10-05-1995				
SOP	AQ	wo	95/27071	Α	University of Texas	10-12-1995				
SOP	AR	wo	96/14061	Α	Cell Genesys, Inc.	05-17-1996				


A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner SigNat.	Szott D. Pnih	Date Considered	8/12/02	
---------------------	---------------	--------------------	---------	--

<sup>&</sup>lt;sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.







Please type a plus sign (+) inside this box --

PTO/SB/08A/B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

		Complete if Known
Substitute for form 1449A/B/PTO	Application Number	09/964,065
OT INFORMATION DISCLOSURE	Filing Date	September 26, 2001
STATEMENT BY APPLICANT	First Named Inventor	KOVESDI, Imre
<b>/</b>	Group Art Unit	1636 /632
FEB 1 9 2002 (Use as many sheets as necessary)	Examiner Name	
Sheet 2 of 2	Attorney Docket Number	213257

on PTD-892

X	K /	2   2							
THAL	JE W. K.								
		OTHER - NON PATENT LITERATURE DOCUMENTS	T	1-4:					
Examiner Initials¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*					
508	AS	ARMENTANO et al., Hum. Gene Ther., 6, 1343-1353 (October 1995).							
508	AT	et al., Gene Ther., 1, 51-58 (1994).							
508	AU	BERKNER et al., Nucl. Acids Res., 11 (17), 6003-6020 (September 1983).							
SDP	A۷	BERKNER, BioTechniques, 6 (7), 616-629 (July/August 1988).	RKNER, BioTechniques, 6 (7), 616-629 (July/August 1988).						
SDP	AW	BOUCHER et al., Hum. Gene Ther., 5, 615-639 (1994).							
SDP	AX	BROUGH et al., Virology, 190 (2), 624-634 (October 1992).							
SOP	AY BROUGH et al., Virology, 196 (1), 269-281 (1993).								
	AZ-	BRUNET et al., Mol. Cell. Biol., 8 (11), 4799-4807 (November 1988).							
SOP	BA	CRYSTAL et al., Nature Med., 1 (1), 15-17 (1995).							
Sop	ВВ	DAVIDSON et al., J. Virol., 61 (4), 1226-1239 (April 1987).							
508	ВС	DeMATTEO et al., Transplantation 63 (2), 315-319 (1997).							
SOP	BD	ENGELHARDT et al., PNAS USA, 91 (13), 6196-6200 (June 1994).							
500	BE	ENGLEHARDT et al., Hum. Gene Ther., 4 (6), 759-769 (December 1993).							
SDP	BF	FALLAUX et al., Hum. Gene Ther., 7, 215-222 (January 20, 1996).							
50°	BG	FRIEDMANN et al., Scientific American, 96-101 (June 1997).							
SDP	ВН	GILARDI et al., FEBS Lett., 267 (1), 60-62 (July 1990).							
SDP	BI	GRAHAM et al., J. Gen. Virol., 36 (1), 59-74 (July 1977).							
	₽J	ORODZICKER et al., Cell, 21 (2), 453-463 (September 1980). 70 copy							
50P	BK	IMLER et al., Gene Ther., 3, 75-84 (1996).							
508	BL	KLESSIG et al., Mol. Cell Biol., 4 (7), 1354-1362 (July 1984).							
508	ВМ	KREEGER, "Hot Papers: Gene Therapy," The Scientist, 10 (4) (February 19, 1996).							
508	BN	KROUGLIAK et al., Hum. Gene Ther., 6, 1575-1586 (December 1995).							


\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

<sup>+</sup> An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner SigNat.	Szott D. Priche	Date Considered 8//2/02	

<sup>&</sup>lt;sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

On P10.892/



PTO/SB/08A/B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

						Complete if Known	
	Substitute for fo	orm 1449A/B/PTO			Application Number	09/964,065	
,	1 P INFO	ORMATION	DISCL	OSURE	Filing Date	September 26, 2001	
		TEMENT E			First Named Inventor	KOVESDI, Imre	
	1 0 2002				Group Art Unit	1636 1632	
3		ຼື (Use as many she	eets as neces	ssary)	Examiner Name		
13	Sheet	3	of	3	Attorney Docket Number	213257	
	PRAUEN					<u> </u>	

		OTHER - NON PATENT LITERATURE DOCUMENTS	Tran	slation
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No
SDP	ВО	LEMARCHAND et al., <i>PNAS USA</i> , 89 (14), 6482-6486 (July 15, 1992).		
SDP	BP	MASTRANGELI et al., J. Clin. Invest., 91 (1), 225-234 (January 1993).		
SDP	BQ	MITTEREDER et al., Hum. Gene Ther., 5 (6), 771-729 (June 1994).		
SOP	BR	MORIN et al., Mol. Cell Biol., 9 (10), 4372-4380 (October 1989).		
SOP	BS	ORKIN et al., Report and Recommendations to the Panel to Assess NIH Investment in Research on Gene Ther. (1995).		
	BT	ROBERTS et al., J. Virol., 56 (2), 404-413 (November 1985). 7, 0 copy		
SDP	BU	ROSENFELD et al., Cell, 68 (1), 143-158 (January 10, 1992).		
SDP	в٧	SCHAACK et al., J. Virol., 69, 4079-4085 (July 1995).		
50P	BW	SCHULICK et al., J. Clin. Invest., 99 (2), 209-219 (1997).		
SDP	вх	SIMON et al., Hum. Gene Ther., 4 (6), 771-780 (December 1993).		·
5DP	BY	TRAPNELL et al., Curr. Opin. Biotechnol., 5, 617-625 (1994).		
50°	BZ	VERMA et al., Nature, 389, 239-242 (1997).		
5DP	CA	VOS et al., Virology, 172 (2), 634-642 (October 1989).		
5DP	СВ	WANG et al., Gene Ther., 2, 775-783 (1995).		
SDP	CC	WEINBERG et al., PNAS USA, 80 (17), 5383-86 (September 1983).		
5»P	CD	YANG et al., PNAS USA, 91 (10), 4407-4411 (May 1994).		
50P	CE	YEH et al., J. Virol., 70 (1), 559-565 (January 1996).		

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner SigNat.	with D. Pricke	Date Considered	8/12/02
------------------	----------------	--------------------	---------

<sup>&</sup>lt;sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.